Home » Stocks » EIGR

Eiger BioPharmaceuticals, Inc. (EIGR)

Stock Price: $8.54 USD -0.11 (-1.27%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 289.94M
Revenue (ttm) 3.65M
Net Income (ttm) -20.56M
Shares Out 33.89M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $8.54
Previous Close $8.65
Change ($) -0.11
Change (%) -1.27%
Day's Open 8.60
Day's Range 8.21 - 8.90
Day's Volume 259,732
52-Week Range 7.57 - 13.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PALO ALTO, Calif., May 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted the...

5 days ago - PRNewsWire

PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

1 week ago - PRNewsWire

PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies...

2 weeks ago - PRNewsWire

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of fou...

1 month ago - PRNewsWire

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announces that results from the Phase 2 PREVENT study of Avexitide in patients with severe Post-Bariatric Hypoglycemia (PBH) were published in the Journal of ...

2 months ago - Benzinga

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg ann...

Other stocks mentioned: AAPL, CAT, CLSD, DIS, DOW, INTC, JNJ ...
4 months ago - Seeking Alpha

Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Priority Review...

5 months ago - Seeking Alpha

PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare dise...

5 months ago - PRNewsWire

Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

5 months ago - Zacks Investment Research

The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-deficie...

5 months ago - Benzinga

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-ra...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 2, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ...

6 months ago - PRNewsWire

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

6 months ago - Zacks Investment Research

Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive

6 months ago - Seeking Alpha

Investors were excited about the company's positive results from a COVID-19 clinical study

6 months ago - The Motley Fool

Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.

7 months ago - Zacks Investment Research

The company reported disappointing news from a clinical study targeting COVID-19 outpatients.

7 months ago - The Motley Fool

Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) has announced disappointing results from an investigator-sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID...

7 months ago - 24/7 Wall Street

Short-term catalyst is the near-certain approval of lonafarnib in HGPS.

7 months ago - Seeking Alpha

Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

PALO ALTO, Calif., Aug. 31, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

8 months ago - PRNewsWire

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients

Other stocks mentioned: REGN
9 months ago - Seeking Alpha

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, BSGM, CYDY, GILD, IMUX, PFE ...
9 months ago - Seeking Alpha

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

PALO ALTO, Calif., May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, reco...

11 months ago - PRNewsWire

PALO ALTO, Calif., May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare disea...

11 months ago - PRNewsWire

PALO ALTO, Calif., May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare disea...

11 months ago - PRNewsWire

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials

11 months ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals

1 year ago - Zacks Investment Research

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

1 year ago - Zacks Investment Research

Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

EIGR has an NDA upcoming for an ultrarare disease, but another phase 3 trial ongoing for the first antiviral against the hepatitis D virus.

1 year ago - Seeking Alpha

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Other stocks mentioned: BHVN, CALA, RMTI
1 year ago - 24/7 Wall Street

About EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the tre... [Read more...]

Industry
Biotechnology
CEO
David Cory
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
EIGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is 31.67, which is an increase of 270.84% from the latest price.

Price Target
$31.67
(270.84% upside)
Analyst Consensus: Strong Buy